Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center

Pharmacotherapy

Volumn 30, Issue 9, 2010, Pages 895-903

  Minson, Quentin ^a   Gentry, Chris A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anemia; Drug safety; Infectious diseases; Linezolid; Thrombocytopenia

Indexed keywords

HEMOGLOBIN; LINEZOLID;

ABDOMINAL INFECTION; ADULT; AGED; ANEMIA; ARTICLE; BACTEREMIA; BACTERIAL ARTHRITIS; BLEEDING; BLOOD TOXICITY; CATHETER INFECTION; CLINICAL PRACTICE; COMORBIDITY; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HEMATOCHEZIA; HUMAN; HYPOCALCEMIA; HYPONATREMIA; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; NEUTROPENIA; OPTIC NERVE DISEASE; OSTEOMYELITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; PUBLIC HOSPITAL; SEROTONIN SYNDROME; SKIN INFECTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

ACETAMIDES; AGED; ANEMIA; ANTI-INFECTIVE AGENTS; BLOOD PLATELETS; FEMALE; HEMATOLOGIC DISEASES; HOSPITALS, VETERANS; HUMANS; INPATIENTS; MALE; MIDDLE AGED; OUTPATIENTS; OXAZOLIDINONES; PLATELET COUNT; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 77956134800     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.9.895     Document Type: Article

References (16)

1. Pfizer Inc. Zyvox (linezolid) product information. New York, NY; 2008.
2. Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005;33:1529-33. (Pubitemid 40980608)
3. Vinken AG, Li JZ, Balan DA, et al. Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in U.S. hospitals. Am J Ther 2003;10:264-74.
4. Attassi K, Hershberger E, Alam R, et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002;34:695-8.
5. Rao N, Ziran BH, Hall RA, et al. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res 2004;427:67-71.
6. Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006;50:1599-602.
7. Rucker JC, Hamilton SR, Bardenstein MD, et al. Linezolid-associated toxic optic neuropathy. Neurology 2006;66:595-8.
8. Rho JP, Sia IG, Crum BA, et al. Linezolid-associated peripheral neuropathy. Mayo Clin Proc 2004;79:927-30.
9. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Clinical research policies and standard procedure documents. Available from http://www3.niaid. nih.gov/research/resources/DMIDClinRsrch/toxtables.htm. Accessed September 24, 2007.
10. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003;2:148-57.
11. U.S. Food and Drug Administration. Transcripts of the antiinfective drugs advisory committee. Gaithersburg, MD: Food and Drug Administration, Center for Drug Evaluation and Research, March 24, 2000.
12. Waldrep TW, Skiest DJ. Linezolid-induced anemia and thrombocytopenia. Pharmacotherapy 2002;22:109-12.
13. Orrick JJ, Johns T, Janelle J, Ramphal R. Thrombocytopenia secondary to linezolid administration: what is the risk [letter]? Clin Infect Dis 2002;35:348-9.
14. Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006;42:66-72. (Pubitemid 41832082)
15. Senneville E, Legout L, Valette M, et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother 2004;54:798-802.
16. Moise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002;50:1017-26.